Picture of Taisho Pharmaceutical Holdings Co logo

4581 — Taisho Pharmaceutical Holdings Co News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Taisho said to near $1.6 bln deal for Bristol-Myers's UPSA- Bloomberg (updated)

* Companies decline to comment
    * Taisho's sales of OTC drugs down year-on-year in
April-Sept

 (Adds details on Taisho)
    Dec 16 (Reuters) - Japanese healthcare firm Taisho
Pharmaceutical Holdings Co Ltd  4581.T  is said to be close to a
$1.6 billion deal for Bristol-Myers Squibb Co's  BMY.N  French
over-the-counter drugs business UPSA, Bloomberg reported on
Sunday, citing sources familiar with the matter.
    An agreement for the consumer-health business could be
announced as soon as this week, according to the report https://bloom.bg/2QyHulF.
    Bristol-Myers Squibb declined to comment on the report, but
said it was still considering options for the strategic review
of UPSA that was announced in June. A Taisho spokesman declined
to comment.
    The report comes amid a flurry of deals among drugmakers,
who are trying to survive a contraction in the domestic drug
market due to government-led price cuts and promotion of generic
drugs.
    The Japanese drugmaker's sales of over-the-counter drugs in
foreign markets was worth 8.8 billion yen in April-September,
down 7.9 percent on year, according to its results.
    Earlier this month, Takeda Pharmaceutical  4502.T  won
shareholder approval for its $59 billion takeover of
London-listed Shire  SHP.L , allowing the company to join the
ranks of the world's top 10 drugmakers. urn:newsml:reuters.com:*:nL4N1YA1TD
    German drugmaker Stada  STAGn.D  and Italian healthcare
company Angelini were among the final bidders for Bristol-Myers'
UPSA unit, according to a Reuters report in November.
 urn:newsml:reuters.com:*:nL8N1XJ9IA
    Taisho shares ended down 0.3 percent at 12,560 yen on
Monday.

 (Reporting by Bhanu Pratap in Bengaluru; Additional reporting
by Philip George in Bengaluru; Editing by Sunil Nair)
 ((Bhanu.Pratap@thomsonreuters.com; (within U.S. +1 646 223
8780, outside U.S. +91 80 6749 3581);))

Recent news on Taisho Pharmaceutical Holdings Co

See all news